These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 17593120

  • 1. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
    Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, Allen AJ, Ball S, Dunn D.
    Dev Med Child Neurol; 2007 Jul; 49(7):498-502. PubMed ID: 17593120
    [Abstract] [Full Text] [Related]

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 3. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
    Polzer J, Bangs ME, Zhang S, Dellva MA, Tauscher-Wisniewski S, Acharya N, Watson SB, Allen AJ, Wilens TE.
    Biol Psychiatry; 2007 Mar 01; 61(5):713-9. PubMed ID: 16996485
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov 01; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
    Panei P, Arcieri R.
    Recenti Prog Med; 2013 Jun 01; 104(6):254-61. PubMed ID: 23801229
    [Abstract] [Full Text] [Related]

  • 10. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb 01; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

  • 11. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications.
    McAfee AT, Landon J, Jones M, Bangs ME, Acharya N, Hornbuckle K, Wong J.
    Pharmacoepidemiol Drug Saf; 2013 Apr 01; 22(4):386-93. PubMed ID: 23280590
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun 01; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    Atomoxetine ADHD and Comorbid MDD Study GroupLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. bangsme@lilly.com, Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, Busner J, Duesenberg DA, Harshawat P, Kaplan SL, Quintana H, Allen AJ, Sumner CR.
    J Child Adolesc Psychopharmacol; 2007 Aug 01; 17(4):407-20. PubMed ID: 17822337
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.
    Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D.
    J Clin Psychopharmacol; 2004 Feb 01; 24(1):30-5. PubMed ID: 14709944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.